BioSpace News Archive

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients who received RADICAVA® (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS).

From standing up COVID-19 units overnight to vaccinating the first nurse in Florida, Tampa General Hospital team members have worked tirelessly to care for COVID-19 patients and for all patients and their families.

Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of March 31, 2021 and its revenues for the first quarter of 2021

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, has provided financial results for the first quarter ended March 31, 2021.

Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today that Mario Saltarelli, M.D., Ph.D., CEO of U.S. Green Valley Pharmaceuticals, has been appointed to Verge’s Scientific Advisory Board.

- Building on Statistically Significant Findings from Phase 2 CENTAUR Trial, PHOENIX to Include 600 People with ALS and Broader Inclusion Criteria - Trial in Europe and U.S. Expected to Begin in Q3 2021 to Support Regulatory Submissions

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during a virtual CD19 Forum on May 19, 2021 at 2:30 PM Pacific Time/5:30 PM Eastern Time.

IntelGenx Corp. announced that it has entered into a second feasibility agreement with ATAI Life Sciences AG

Company’s Second Major Acquisition Will Extend Orphan and Rare Disease Research Base and Growth Opportunities

As the focus on the COVID-19 pandemic shifts to raising the number of vaccinated people around the world, U.S. researchers, funded by the NIH, are undertaking a large new clinical trial to find effective treatments, in the belief that while controllable, SARS-Cov-2 and its variants will continue to cause endemic disease in many parts of the world.